Browsing by Author "Yumuk, Perran Fulden"
Now showing items 1-11 of 11
-
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases
Batur, Şebnem; Dülger, Onur; Durak, Şermin; Yumuk, Perran Fulden; Çağlar, Hale Başak; Bozkurtlar, Emine; Bozkurt, Süheyla; Taştekin, Ebru; Çiçin, İrfan; Ahiskalı, Rengin; Çakır, Aslı; Öz, Büge (2020)Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially ... -
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Ireland Ltd, 2020)Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Science Inc, 2021)... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
Kılıçkap, Saadettin; Demirci, Umut; Buğdaycı, Fatma; Tural, Deniz; Korkmaz, Taner; Paydaş, Semra; Yılmaz, Coşkun; Tuna, Hande; Sezer, Ahmet; Yeşil Çinkir, Havva; Erman, Münire; Eralp, Yeşim; Çabuk, Devrim; Işıkdoğan, Abdurrahman; Demirkazık, Ahmet; Karaoğlu, Aziz; Yazılıtaş, Doğan; Çay Şenler, Filiz; Yumuk, Perran Fulden; Coşkun, Hatice; Yıldız, İbrahim; Öztop, İlhan; Beypınar, İsmail; Aydın, Kübra; Kaplan, M.; Meydan, Nezih; Ölmez, Ömer Fatih; Seber, Samile; Arslan, Çağatay; Şendur, Mehmet Ali Nahit; Çiçin, İrfan (Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ... -
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
Batırel, Hasan Fevzi; Metintaş, Muzaffer; Çağlar, Hale Başak; Ak, Güntülü; Yumuk, Perran Fulden; Ahıskalı, Rengin; Bozkurtlar, Emine; Bekiroğlu, Nural; Laçin, Tunç; Yıldızeli, Bedrettin; Yüksel, Mustafa (Mosby-Elsevier, 2018)Objective: Macroscopic complete resection (MCR) is the recommended surgical strategy in malignant pleural mesothelioma. Our objective was to analyze whether MCR influences survival in malignant pleural mesothelioma. Methods: ... -
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Esin, Ece; Çakmak Öksüzoğlu, Ömür Berna; Bilici, Ahmet; Çiçin, İrfan; Aksoy, Sercan; Alacacıoğlu, Ahmet; Kaplan, Mehmet Ali; Çabuk, Devrim; Sümbül, Ahmet Taner; Paydaş, Semra; Sakin, Ayşegül; Korkmaz, Tuba; Özdemir Yıldırım, Nuriye; Artaç, Mehmet; Harputluoğlu, Hakan; Yumuk, Perran Fulden; Atalay Başaran, Gül; Oyan Uluç, Başak; Demirci, Umut (Oxford University Press, 2018)... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ... -
Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients
Umar, Rashida Muhammad; Apikoğlu-Rabuş, Şule; Yumuk, Perran Fulden (Springer, 2020)Background The use of highly toxic drugs in cancer treatment and supportive care medications exposes patients to an increased number of drug-related problems (DRPs). Clinical pharmacists contribute to the optimal use of ...